Pfizer's Pneumococcal Vaccine Could See a Boost in Sales After the CDC's Recommendation for Use in Older Adults

Pfizer’s Prevnar 13 Could See a $2 Billion Boost in Sales

Pfizer’s Pneumococcal Vaccine Could See a Boost in Sales After the CDC’s Recommendation for Use in Older Adults On Wednesday, Pfizer announced that the CDC’s Advisory Committee on Immunisation Practices (ACIP) has decided to recommend and promote the Prevnar 13 pneumococcal vaccine for use in adults aged 65 and up. The vaccine protects against pneumococcal diseases including pneumonia, which can …